查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1993878

mRNA疫苗和治療市場：全球產業分析、市場規模、市場佔有率及按治療方法、類型、應用、最終用戶、國家和地區分類的預測——2026-2033年

mRNA Vaccines And Therapeutics Market, By Treatment Type, By Type, By Application, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 339 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，mRNA 疫苗和治療藥物市場價值將達到 29.8076 億美元，並將在 2026 年至 2033 年期間以 30.6% 的複合年成長率成長。

mRNA疫苗和療法是一種先進的生物技術解決方案，它利用傳訊RNA）誘導細胞產生特定蛋白質，從而預防和治療疾病。這種方法使人體免疫系統能夠識別並攻擊目標病原體或異常細胞。基於mRNA的平台利用遺傳訊息誘導可控的蛋白質表達，從而支持針對感染疾病、癌症和其他疾病的疫苗和療法的研發。這些解決方案具有快速開發、精準標靶化和靈活設計等優勢。透過增強免疫反應並加速創新，mRNA疫苗和療法正在推動現代醫學和下一代醫療保健技術的進步。

mRNA疫苗與治療市場－市場動態

慢性病盛行率增加

慢性病盛行率上升指的是全球罹患癌症、心血管疾病和自體免疫疾病等長期疾病的人數不斷增加。人口老化、生活方式改變和環境因素等因素共同推動了這一趨勢，給醫療保健系統帶來了額外的負擔。在mRNA疫苗和療法領域，慢性病負擔的加重正在推動利用mRNA技術靶向特定疾病路徑的創新治療方法的研發。雖然mRNA平台支援個人化標靶治療，但慢性病盛行率的上升正在加速先進生物技術治療方法的研發和投資。慢性病盛行率的上升正在推動臨床研究和開發，並增強現代醫療保健對mRNA疫苗和療法的需求。例如，根據經濟合作暨發展組織，截至2025年11月，心血管疾病、癌症、呼吸道疾病和糖尿病等慢性病仍將是OECD成員國面臨的主要健康負擔。報告指出，2022年，約8.6%的成年人患有糖尿病，超過三分之一的16歲及以上人口患有長期疾病，顯示慢性病負擔日益加重。此外，經合組織報告稱，到2024年，45歲及以上基層醫療使用者中，82%至少患有一種慢性病，52%患有兩種或兩種以上慢性病，這凸顯了慢性病患病率的上升以及對有效長期醫療保健管理日益成長的需求。

mRNA疫苗與治療市場－市場區隔分析：

全球mRNA疫苗和療法市場按治療類型、類別、應用、最終用戶和地區進行細分。

根據治療類型，市場可分為三大類：單株抗體、基因療法和細胞療法。單株抗體因其在標靶疾病治療中的有效性而佔據了較大的市場佔有率。標靶疾病療法是指旨在識別並作用於與疾病相關的特定細胞、蛋白質或路徑的治療方法。這種方法提高了治療的精準性，改善了臨床療效，並最大限度地減少了對健康細胞的損傷。在mRNA疫苗和治療領域，單株抗體被廣泛用於支持癌症、感染疾病和自體免疫疾病等疾病的免疫療法。這些治療方法透過中和有害病原體、抑制致病機制和增強免疫反應，有助於實現更有效、更先進的治療方案。例如，根據國際藥品製造商協會聯合會（IFPMA）的數據，截至2025年2月，包括單株抗體在內的生物製藥將使全球超過3.5億患者受益，用於治療癌症、糖尿病和罕見疾病。本報告也重點介紹了藥物創新持續發展的趨勢。 2023 年，全球推出了 69 種新的活性成分；截至 2024 年 10 月，超過 12700 種藥物處於不同的臨床開發階段，反映出先進生物製藥和抗體治療方法的強勁成長。

根據類型，mRNA疫苗市場分為兩大類：自擴增mRNA疫苗和傳統非擴增mRNA疫苗。自擴增mRNA疫苗因其能夠增強蛋白質表現並降低劑量，佔據了市場的大部分佔有率。增強蛋白表現是指自擴增mRNA疫苗能夠在細胞內複製RNA，產生更高水平的抗原並誘導更強的免疫反應。在自擴增mRNA疫苗中，這種增強的表達能夠擴大免疫覆蓋範圍，從而可能減少加強劑的接種次數，並對新出現的病原體做出快速反應。這些優勢使得自擴增mRNA疫苗在感染疾病、腫瘤和個人化醫療等領域極具應用前景，推動了mRNA疫苗技術在全球範圍內的快速發展和普及。例如，根據英國藥品和保健產品監管局 (MHRA) 的數據，2026 年 1 月，英國核准了自擴增 mRNA 新冠疫苗“Zapomeran (Kostaive)”，用於 18 歲及以上成年人。這標誌著自擴增 mRNA 疫苗（一種用於公共衛生應對的下一代疫苗）首次獲得監管部門核准。該疫苗以 0.5 毫升的單次加強劑量接種，含有自擴增傳訊RNA，旨在刺激人體產生 SARS-CoV-2 刺突蛋白，從而增強對新冠病毒的免疫力。

mRNA疫苗和治療市場—區域洞察

mRNA疫苗和療法市場受醫療基礎設施、研發投入和技術應用差異的影響，呈現明顯的區域性差異。在北美，尤其是在美國和加拿大，基於mRNA的治療方法正在逐步普及，臨床試驗廣泛開展，人們對個人化醫療的興趣日益濃厚。歐洲市場呈現穩定成長態勢，這得益於生物技術投資的增加、法規結構的支持以及創新疫苗平台的推出。亞太地區市場正在快速擴張，這主要得益於醫療服務可及性的提高、龐大的患者群體、政府支持的加強以及中國、印度、日本和韓國等國家本土生物技術能力的提升。相較之下，拉丁美洲和中東及非洲地區的市場佔有率正在不斷擴大，這得益於醫療基礎設施的改善、人們對mRNA療法的認知度不斷提高以及對臨床研究和疫苗項目的參與度不斷提高。

日本mRNA疫苗和治療市場—國家概況

由於完善的醫療基礎設施和生物技術創新的快速應用，日本mRNA疫苗和療法市場正經歷穩定成長。醫療機構和研究機構擴大利用mRNA疫苗和療法來支持感染疾病預防和個人化醫療。國內外主要製藥公司的積極參與，以及政府支持疫苗研發和核准的政策，持續推動市場擴張。此外，日本日益重視改善公共衛生狀況和推進免疫接種計劃，也進一步加速了mRNA疫苗和療法在日本醫療和研究領域的應用。例如，根據英聯邦基金會的一項調查，到2025年，日本的法定醫療保險制度將涵蓋約98.3%的人口，確保在基於居住和工作地的強制性保險制度下，幾乎全民都能獲得住院治療、初級和專科醫療服務以及處方藥。政府制定醫療保險報銷標準，並向地方政府和保險公司提供津貼，以維持醫療品質和可負擔性。另一方面，根據年齡和收入的不同，每年最高自付費用為 340,000 至 2,120,000 日元（3,400 至 21,200 美元），這表明政府繼續支持全面的醫療保健覆蓋和經濟保障政策。

目錄

第1章：mRNA疫苗和治療市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：mRNA疫苗和治療藥物的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：mRNA疫苗與治療產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：mRNA疫苗與治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：mRNA疫苗和治療藥物的市場趨勢

  • mRNA疫苗和治療藥物市場佔有率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 mRNA疫苗與治療市場：依治療類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 細胞療法
    • 基因治療
    • 單株抗體
    • 其他

第8章 mRNA疫苗和治療市場：按類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按類型
    • 常規非擴增mRNA疫苗
    • 自擴增mRNA疫苗

第9章 mRNA疫苗與治療市場：依應用分類

  • 概述
    • 基於細分市場的市場佔有率分析：按應用領域
    • 自體免疫疾病
    • 癌症
    • 感染疾病
    • 其他

第10章 mRNA疫苗與治療市場：依最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按類型
    • 診所
    • 醫院
    • 研究機構和組織
    • 其他

第11章：mRNA疫苗和治療市場：按地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他中東和非洲國家

第12章 主要供應商分析：mRNA疫苗與治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • AstraZeneca
    • Arcturus Therapeutics
    • BioNTech SE
    • CureVac NV
    • Daiichi Sankyo
    • Ethris
    • GlaxoSmithKline
    • Innovac Therapeutics
    • Kernal Biologics
    • Pantherna Therapeutics
    • pHion Therapeutics
    • Pfizer Inc.
    • Recode Therapeutics
    • Rejuvenation Technologies
    • RNAimmune
    • Strand Therapeutics
    • Moderna, Inc.
    • Walvax
    • Ziphius Vaccines
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV6180

mRNA Vaccines And Therapeutics Market size was valued at US$2,980.76 Million in 2025, expanding at a CAGR of 30.6% from 2026 to 2033.

mRNA Vaccines And Therapeutics refer to a class of advanced biotechnology solutions that use messenger RNA to instruct cells to produce specific proteins for disease prevention or treatment. This approach enables the body's immune system to recognize and respond to targeted pathogens or abnormal cells. mRNA-based platforms utilize genetic instructions to trigger controlled protein production, supporting the development of vaccines and therapeutic applications for infectious diseases, cancer, and other medical conditions. These solutions offer advantages such as rapid development, precise targeting, and flexible design. By enhancing immune response and enabling faster innovation, mRNA Vaccines And Therapeutics contribute to the advancement of modern medicine and next-generation healthcare treatments.

mRNA Vaccines And Therapeutics Market- Market Dynamics

Increasing Prevalence Of Chronic Diseases

Increasing prevalence of chronic diseases refers to the growing number of individuals affected by long-term medical conditions such as cancer, cardiovascular diseases, and autoimmune disorders worldwide. This trend is driven by factors including aging populations, lifestyle changes, and environmental influences, which are placing greater pressure on healthcare systems. In the context of mRNA Vaccines And Therapeutics, the rising burden of chronic diseases is encouraging the development of innovative treatment approaches that utilize mRNA technology to target specific disease pathways. mRNA platforms support personalized targeted therapies while rising chronic disease prevalence accelerates research and investment in advanced biotechnology treatments. The increasing prevalence of chronic diseases drives clinical research and therapeutic development, strengthening the demand for mRNA Vaccines And Therapeutics in modern healthcare.For instance, in November 2025, according to the Organisation for Economic Co-operation and Development (OECD), chronic conditions such as cardiovascular diseases, cancer, respiratory diseases, and diabetes remain major health burdens across OECD countries. The report highlights that around 8.6% of the adult population was living with diabetes in 2022, and over one-third of people aged 16 and above reported having a long-standing illness, indicating a substantial and growing chronic disease burden. The OECD further notes that 82% of primary care users aged 45 and older reported at least one chronic condition in 2024, with 52% experiencing two or more conditions, emphasizing the increasing prevalence of chronic diseases and the rising need for effective long-term healthcare management.

mRNA Vaccines And Therapeutics Market- Segmentation Analysis:

The Global mRNA Vaccines And Therapeutics Market is segmented on the basis of Treatment Type, Type, Application, End User, and Region.

The market is divided into three categories based on treatment type: monoclonal antibody, gene therapy, and cell therapy. The monoclonal antibody segment accounts for a significant portion of the market due to its effectiveness in targeted disease treatment. Targeted disease treatment refers to therapeutic approaches designed to specifically identify and act on particular cells, proteins, or pathways associated with a disease. This method enhances treatment precision, improves clinical outcomes, and minimizes damage to healthy cells. In the context of mRNA Vaccines And Therapeutics, monoclonal antibodies are widely used to support immune-based therapies for conditions such as cancer, infectious diseases, and autoimmune disorders. These treatments help neutralize harmful pathogens, block disease-causing mechanisms, and strengthen immune responses, contributing to more effective and advanced therapeutic solutions. For instance, in February 2025, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), biologic medicines including monoclonal antibodies already benefit more than 350 million patients globally for the treatment of diseases such as cancer, diabetes, and rare disorders. The report also highlights the continued expansion of pharmaceutical innovation, with 69 novel active substances launched globally in 2023 and over 12,700 medicines in different phases of clinical development as of October 2024, reflecting strong growth in advanced biologic and antibody-based therapies.

The market is divided into two categories based on type: self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines. The Self-Amplifying mRNA-Based Vaccines segment accounts for a significant portion of the market due to its enhanced protein expression and dose-sparing potential. Enhanced protein expression refers to the ability of self-amplifying mRNA vaccines to replicate their RNA within cells, producing higher levels of antigen and eliciting stronger immune responses. In self-amplifying mRNA-based vaccines, this increased expression allows for broader immune coverage, potentially fewer booster doses, and faster response to emerging pathogens. These advantages make self-amplifying mRNA vaccines highly attractive for applications in infectious diseases, oncology, and personalized therapeutics, supporting the rapid growth and adoption of mRNA vaccine technologies globally. For instance, in January 2026, according to the UK Government Medicines and Healthcare Products Regulatory Agency, Zapomeran (Kostaive), a self-amplifying mRNA COVID-19 vaccine for adults aged 18 years and older in the UK, was approved, marking one of the first regulatory authorizations of an sa-mRNA vaccine and highlighting a shift toward next-generation mRNA technology in public health responses, with the vaccine administered as a single 0.5 mL booster dose containing self-amplifying messenger RNA designed to help the body make the SARS-CoV-2 spike protein and strengthen immunity against COVID-19.

mRNA Vaccines And Therapeutics Market- Geographical Insights

The mRNA Vaccines And Therapeutics Market exhibits clear regional variation, shaped by differences in healthcare infrastructure, R&D investment, and technology adoption. North America shows growing adoption of mRNA-based therapies, widespread clinical trials, and increasing focus on personalized medicine, particularly in the U.S. and Canada. Europe demonstrates consistent growth, driven by rising investments in biotechnology, supportive regulatory frameworks, and the adoption of innovative vaccine platforms. Asia Pacific is expanding rapidly, fueled by rising healthcare access, large patient populations, increasing government support, and the development of local biotechnology capabilities in countries such as China, India, Japan, and South Korea. In contrast, Latin America, the Middle East, and Africa are developing their market presence, supported by improving healthcare infrastructure, growing awareness of mRNA therapeutics, and increasing participation in clinical research and vaccine programs.

Japan mRNA Vaccines And Therapeutics Market - Country Insights

The Japan mRNA Vaccines And Therapeutics market is experiencing consistent growth, driven by a well-developed healthcare infrastructure and rapid adoption of biotechnology innovations. Healthcare providers and research institutions are increasingly utilizing mRNA Vaccines And Therapeutics to prevent infectious diseases and support personalized medicine initiatives. Strong participation from leading domestic and global pharmaceutical companies, along with supportive government policies for vaccine development and approval, continues to encourage market expansion. Additionally, growing emphasis on improving public health outcomes and advancing immunization programs is further accelerating adoption across healthcare and research settings in Japan. For instance, in 2025, according to the Commonwealth Fund's organization, Japan's statutory health insurance system covers about 98.3% of the population, ensuring nearly universal access to hospital care, primary and specialty services, and prescription drugs under mandatory residence- and employment-based plans; the national government sets the health insurance fee schedule and subsidizes local governments and insurers to maintain quality and affordability, while out-of-pocket maximums range from JPY 340,000 to 2.12 million annually (USD 3,400-21,200) depending on age and income, demonstrating sustained government policy support for comprehensive healthcare coverage and financial protection.

mRNA Vaccines And Therapeutics Market- Competitive Landscape:

The mRNA Vaccines And Therapeutics Market is moderately concentrated, with several leading biotechnology and pharmaceutical companies driving competition. Key players include Pfizer Inc., Moderna, Inc., BioNTech SE, GlaxoSmithKline, Daiichi Sankyo, CureVac N.V., AstraZeneca, Ethris, Sanofi, Arcturus Therapeutics, Innovac Therapeutics, Kernal Biologics, Pantherna Therapeutics, pHion Therapeutics, Recode Therapeutics, Rejuvenation Technologies, RNAimmune, Strand Therapeutics, Walvax, and Ziphius Vaccines. These companies compete by developing innovative mRNA-based vaccines and therapeutics for infectious diseases, oncology, and personalized medicine. For example, in 2024, Moderna, Inc. advanced its mRNA vaccine platform to include self-amplifying mRNA technology, enabling enhanced protein expression, improved immune responses, and faster adaptation to emerging pathogens. The market is driven by increasing demand for effective, rapid-response vaccines and therapeutics, particularly in the context of emerging infectious diseases and cancer immunotherapy. Additionally, companies are expanding capabilities with enhanced delivery systems, multi-dose formulations, predictive immunogenicity modeling, and scalable manufacturing platforms to meet the evolving needs of healthcare systems and the growing preference for innovative, accessible, and safe mRNA-based treatments.

Recent Developments:

In 2025, Pfizer Inc. announced a collaboration with a leading biotechnology partner to develop next-generation mRNA vaccines aimed at improving immune response, expanding protection against emerging infectious diseases, and enhancing vaccine delivery efficiency. This initiative demonstrates Pfizer's commitment to leveraging cutting-edge mRNA technology to advance global health, potentially establishing a new standard in vaccine innovation. The partnership is set to utilize self-amplifying mRNA and enhanced delivery platforms, positioning Pfizer as a leader in innovative mRNA therapeutics.

In 2024, Kernal Biologics initiated a joint project with a prominent research institute to develop advanced mRNA therapeutics for oncology and personalized medicine applications. The collaboration focuses on optimizing mRNA design, delivery systems, and immunogenicity to improve patient outcomes. By integrating scalable manufacturing processes and predictive modeling, Kernal Biologics aims to strengthen its position as a key innovator in next-generation mRNA-based therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca
  • Arcturus Therapeutics
  • BioNTech SE
  • CureVac N.V.
  • Daiichi Sankyo
  • Ethris
  • GlaxoSmithKline
  • Innovac Therapeutics
  • Kernal Biologics
  • Pantherna Therapeutics
  • pHion Therapeutics
  • Pfizer Inc.
  • Recode Therapeutics
  • Rejuvenation Technologies
  • RNAimmune
  • Strand Therapeutics
  • Moderna, Inc.
  • Walvax
  • Ziphius Vaccines
  • Others

GLOBALMRNA VACCINES AND THERAPEUTICS MARKET, BY TREATMENT TYPE - MARKET ANALYSIS, 2020 - 2033

  • Cell Therapy
  • Gene Therapy
  • Monoclonal Antibody
  • Other

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY TYPE - MARKET ANALYSIS, 2020 - 2033

  • Conventional Non-Amplifying mRNA-Based Vaccines
  • Self-Amplifying mRNA-based Vaccines

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Autoimmune Diseases
  • Cancer
  • Infectious Diseases
  • Others

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Clinics
  • Hospitals
  • Research Laboratories and Organizations
  • Others

GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. mRNA Vaccines And Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. mRNA Vaccines And Therapeutics Market Snippet by Treatment Type
    • 2.1.2. mRNA Vaccines And Therapeutics Market Snippet by Type
    • 2.1.3. mRNA Vaccines And Therapeutics Market Snippet by Application
    • 2.1.4. mRNA Vaccines And Therapeutics Market Snippet by End User
    • 2.1.5. mRNA Vaccines And Therapeutics Market Snippet by Country
    • 2.1.6. mRNA Vaccines And Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. mRNA Vaccines And Therapeutics Key Market Trends

  • 3.1. mRNA Vaccines And Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. mRNA Vaccines And Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. mRNA Vaccines And Therapeutics Market Opportunities
  • 3.4. mRNA Vaccines And Therapeutics Market Future Trends

4. mRNA Vaccines And Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. mRNA Vaccines And Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. mRNA Vaccines And Therapeutics Market Landscape

  • 6.1. mRNA Vaccines And Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. mRNA Vaccines And Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2025&2033 (%)
    • 7.1.2. Cell Therapy
    • 7.1.3. Gene Therapy
    • 7.1.4. Monoclonal Antibody
    • 7.1.5. Other

8. mRNA Vaccines And Therapeutics Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
    • 8.1.2. Conventional Non-Amplifying mRNA-Based Vaccines
    • 8.1.3. Self-Amplifying mRNA-based Vaccines

9. mRNA Vaccines And Therapeutics Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2025&2033 (%)
    • 9.1.2. Autoimmune Diseases
    • 9.1.3. Cancer
    • 9.1.4. Infectious Diseases
    • 9.1.5. Others

10. mRNA Vaccines And Therapeutics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
    • 10.1.2. Clinics
    • 10.1.3. Hospitals
    • 10.1.4. Research Laboratories and Organizations
    • 10.1.5. Others

11. mRNA Vaccines And Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025&2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. mRNA Vaccines And Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. mRNA Vaccines And Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. mRNA Vaccines And Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. mRNA Vaccines And Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAMMarket Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAMMarket Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAMMarket Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAMMarket Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. mRNA Vaccines And Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- mRNA Vaccines And Therapeutics Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AstraZeneca
    • 12.2.2. Arcturus Therapeutics
    • 12.2.3. BioNTech SE
    • 12.2.4. CureVac N.V.
    • 12.2.5. Daiichi Sankyo
    • 12.2.6. Ethris
    • 12.2.7. GlaxoSmithKline
    • 12.2.8. Innovac Therapeutics
    • 12.2.9. Kernal Biologics
    • 12.2.10. Pantherna Therapeutics
    • 12.2.11. pHion Therapeutics
    • 12.2.12. Pfizer Inc.
    • 12.2.13. Recode Therapeutics
    • 12.2.14. Rejuvenation Technologies
    • 12.2.15. RNAimmune
    • 12.2.16. Strand Therapeutics
    • 12.2.17. Moderna, Inc.
    • 12.2.18. Walvax
    • 12.2.19. Ziphius Vaccines
    • 12.2.20. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us